Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection

Hepato-Gastroenterology

Volumn 52, Issue 64, 2005, Pages 1191-1196

  Ljubuncic, Predrag ^a   Konikoff, Fred M ^b   Blendis, Laurence M ^b   Bomzon, Arieh ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Hepatitis C; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; INTERFERON; LIPID PEROXIDE; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; URSODEOXYCHOLIC ACID; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIPID BLOOD LEVEL; LIVER FIBROSIS; LIVER FUNCTION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; CHOLAGOGUES AND CHOLERETICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIPID PEROXIDES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; OXIDATIVE STRESS; RIBAVIRIN; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 21744446706     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Boyer N, Marcellin P: Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000; 32(Suppl 1):98-112.
2. Liang JT, Rehermann B, Seeff LB, Hoofnagle JH: Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jnr FL, Hussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon a2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
4. Alberti A, Benvegnu L: Management of hepatitis C. J Hepatol 2003; 38:S104-S118.
5. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ: Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-890.
6. Levy C, Lindor KD: Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2003; 38:S24-S37.
7. Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB: Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992; 116:624-629.
8. Pageaux GP, Blanc P, Perrigault PF, Navarro F, Fahre JM, Souche B, Domergue J, Larrey D, Michel H: Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation. J Hepatol 1995; 23:119-122.
9. Takano S, Ito Y, Yokosuka M, Uchiumi K, Hirota K, Omata M: A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20:558-564.
10. Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, Spada E, Baroni CD, Capocaccia L: Recombinant interferon-a and ursodeoxycholic acid versus interferon-a alone in the treatment of chronic hepatitis C: A randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995; 90:263-269.
11. Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, Turlin B, Jacquelinet C, Brissot P, Deugnier Y: Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients. Hepatology 1995; 21:322-327.
12. Puoti C, Magrini A, Annovazzi G, Pannullo A, Filippi T: Ursodeoxycholic acid for chronic hepatitis C patients. Hepatology 1995; 22:1002.
13. Senturk H, Uzunalimoglu O, Batur Y, Simsek I, Mert A, Ozbay G, Cetinkaya H, Ersoz G, Tabak F, Akbaylar H, Akdogan M, Dokmeci A, Sonsuz A, Ozenirler S, Erden E, Tozum N: Long-term efficacy of interferon-a and ursodeoxycholic acid in treatment of chronic type C hepatitis. Dig Dis Sci 1997; 42:1438-1444.
14. Clerici C, Distrutti E, Gentili G, Solinas A, Miglietti M, Balo S, Giansanti M, Rusticali AG, Morselli-Labate AM, Morelli A: Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis. Minerva Med 1997; 88:219-225.
15. De Maria N, Colantoni A, Fagiuoli S, Liu G-J, Rogers BK, Farinati F, Van Thiel DH, Floyd RA: Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996; 21:291-295.
16. Romero MJ, Bosch-Morell F, Romero B, Rodrigo JM, Serra MA, Romero FJ: Serum malondialdehyde: Possible use for the clinical management of chronic hepatitis C patients. Free Radic Biol Med 1998; 25:993-997.
17. Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T: Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Comm 1998; 247:166-170.
18. Loguercio C, Federico A: Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 2003; 34:1-10.
19. Higueras V, Raya A, Rodrigo JM, Serra MA, Roma J, Romero FJ: Interferon decreases serum lipid peroxidation products of hepatitis C patients. Free Radic Biol Med 1994; 16:131-133.
20. Mutlu-Turkoglu U, Ademglu E, Turkoglu S, Badur S, Uysal M, Toker G: The effects of interferon-alpha on serum lipid peroxidation and total thiol content in patients with chronic active hepatitis C. Res Commun Mol Pathol Pharmacol 1997; 96:357-361.
21. Look MP, Gerard A, Rao GS, Sudhop T, Fischer H-P, Sauerbruch T, Spengler U: Interferon:antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial. Antiviral Res 1999; 43:113-122.
22. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H: Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 2000; 95:1041-1050.
23. Houglum K, Venkataramani A, Lyche K, Chojkier M: A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113:1069-1073.
24. von Herbay A, Stahl W, Niederau C, Sies H: Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Radic Res 1997; 27:599-605.
25. Paumgartner G, Beuers U: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36:525-531.
26. Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A: Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut 1996; 39:475-478.
27. Ljubuncic P, Tanne Z, Bomzon A: Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease. Dig Dis Sci 2000; 45:1921-1928.
28. Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K, Sakamoto Y, Okanoue T, Kashima K: Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Comm 1999; 263:537-542.
29. Rodriguez-Ortigosa CM, Cincu RN, Sanz S, Ruiz F, Quiroga J, Prieto J: Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut 2002; 50:701-706.
30. Lapenna D, Ciofani G, Festi D, Neri M, Pierdomenico SD, Giamberardino MA, Cuccurullo F: Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol 2002; 64:1661-1667.
31. Serviddio G, Pereda J, Pallardo FV, Carretero J, Borras C, Cutrin J, Vendemiale G, Poli G, Vina J, Sastre J: Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004; 39:711-720.
32. Adams Jr JD, Lanterberg BH, Mitchell JR: Plasma glutathione and glutathione disulfide in the rat: Regulation and response to oxidative stress. J Pharm Exp Therap 1983; 227:749-754.
33. Arguelles S, Garcia S, Maldonado M, Machado A, Ayala A: Do the serum oxidative stress biomarkers provide a reasonable index of the general oxidative stress status? Biochim Biophys Acta 2004; 1674:251-259.
34. Parola M, Robino G: Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35:297-306.
35. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling M-H, Albrecht J: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-1313.
36. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T: Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. Gastroenterology 1999; 116:378-386.
37. Caballero T, Perez-Milena A, Masseroli M, O'Valle F, Salmeron FJ, Del Moral RMG, Sanchez-Salgado G: Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. J Hepatol 2001; 34:740-747.
38. Fujie H, Yotsuyanagi H, Moriya K, Shintani Y, Tsutsumi T, Takayama T, Makuuchi M, Matsuura Y, Miyamura T, Kimura S, Koike K: Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999; 59:141-145.
39. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122:366-375.
40. Azzaroli F, Mehal W, Soroka CJ, Wang L, Lee J, Crispe N, Boyer JL: Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology 2002; 36:49-54.